Dia Beta Labs
Dia Beta Labs is a UK-based biotech company dedicated to transforming the lives of metabolic disease sufferers through the development of novel therapeutic pipeline. With over 30 years of research from Ulster University, they focus on addressing the progressive decline of pancreatic beta-cell health to halt disease progression, developing peptide therapeutics that target previously untapped receptors on beta-cells. Their mission emphasizes innovation, scientific rigor, and collaboration to create disease-modifying treatments for diabetes and obesity.
Industries
Nr. of Employees
small (1-50)
Dia Beta Labs
Products
Therapeutic peptide candidates (preclinical pipeline)
A pipeline of peptide-based therapeutic candidates re-engineered from human hormonal activators and progressed through discovery and preclinical development to address metabolic disease by preventing and reversing beta-cell decline and improving weight-loss outcomes.
Therapeutic peptide candidates (preclinical pipeline)
A pipeline of peptide-based therapeutic candidates re-engineered from human hormonal activators and progressed through discovery and preclinical development to address metabolic disease by preventing and reversing beta-cell decline and improving weight-loss outcomes.
Services
Discovery-stage peptide design, in vitro cellular assays, in vivo rodent efficacy studies, lead optimization and progression through late-stage preclinical development in collaboration with academic and external partners.
Formulation development to improve peptide solubility and enable downstream manufacturing and dosing studies, leveraging external formulation partners where required.
Discovery-stage peptide design, in vitro cellular assays, in vivo rodent efficacy studies, lead optimization and progression through late-stage preclinical development in collaboration with academic and external partners.
Formulation development to improve peptide solubility and enable downstream manufacturing and dosing studies, leveraging external formulation partners where required.
Expertise Areas
- Peptide therapeutic discovery and optimization
- Beta-cell biology and disease modification
- Preclinical efficacy testing in cellular and rodent models
- Formulation development for peptides (CMC-related)
Key Technologies
- Peptide engineering and peptide analogues
- Receptor-targeted agonist development
- Cell-based assays for beta-cell function
- Rodent diabetes and obesity models
News & Updates
Professor Peter Flatt, a world-leading expert in regulatory peptides and experimental diabetes, has been awarded an MBE in the King’s Birthday Honours List, recognizing his significant contributions to diabetes research.
Dia Beta Labs was selected as the overall winner of the annual INVENT Competition for startup companies, securing £25,000 in prize money and gaining recognition for their innovative work in metabolic disease management.
Dia Beta Labs secured a £99K grant from Innovate UK to perform a confirmatory study of their therapeutic lead, DBL002, in female subjects, addressing gender imbalance in preclinical research and demonstrating the drug's weight loss potential in females.
CEO Dr. Ryan Lafferty discussed the company's innovative disease-modifying therapies for diabetes with The Irish Times, emphasizing the importance of holistic and preventative approaches.
CEO Dr. Ryan Lafferty discussed the journey of Dia Beta Labs from academia to industry and their future plans in a 15-minute interview with Business Spotlight UK.
In light of World Diabetes Day, CEO Dr. Ryan Lafferty engaged with The Health Innovation Research Alliance Northern Ireland to discuss innovation in diabetes management.
Professor Peter Flatt, a world-leading expert in regulatory peptides and experimental diabetes, has been awarded an MBE in the King’s Birthday Honours List, recognizing his significant contributions to diabetes research.
Dia Beta Labs was selected as the overall winner of the annual INVENT Competition for startup companies, securing £25,000 in prize money and gaining recognition for their innovative work in metabolic disease management.
Dia Beta Labs secured a £99K grant from Innovate UK to perform a confirmatory study of their therapeutic lead, DBL002, in female subjects, addressing gender imbalance in preclinical research and demonstrating the drug's weight loss potential in females.
CEO Dr. Ryan Lafferty discussed the company's innovative disease-modifying therapies for diabetes with The Irish Times, emphasizing the importance of holistic and preventative approaches.
CEO Dr. Ryan Lafferty discussed the journey of Dia Beta Labs from academia to industry and their future plans in a 15-minute interview with Business Spotlight UK.
In light of World Diabetes Day, CEO Dr. Ryan Lafferty engaged with The Health Innovation Research Alliance Northern Ireland to discuss innovation in diabetes management.